{"product_id":"early-toxicity-testing-market-by-technique-in-vivo-in-vitro-and-in-silico-by-toxicity-endpoint-genotoxicity-dermal-toxicity-skin-toxicity-ocular-toxicity-phototoxicity-and-others-by-end-user-pharmaceutical-industry-cosmetic-industry-chemic","title":"Early Toxicity Testing Market by Technique (In Vivo, In Vitro, and In Silico), by Toxicity Endpoint (Genotoxicity, Dermal Toxicity, Skin Toxicity, Ocular Toxicity, Phototoxicity, and Others), by End User (Pharmaceutical Industry, Cosmetic Industry, Chemic","description":"\u003cp\u003eEarly Toxicity Testing Market by Technique (In Vivo, In Vitro, and In Silico), by Toxicity Endpoint (Genotoxicity, Dermal Toxicity, Skin Toxicity, Ocular Toxicity, Phototoxicity, and Others), by End User (Pharmaceutical Industry, Cosmetic Industry, Chemical Industry, Food Industry, and Others) – Global Opportunity Analysis and Industry Forecast, 2023-2030\u003cbr\u003e\nThe Early Toxicity Testing (ETT) Market size was valued at USD 8.92 billion in 2022, and is predicted to reach USD 14.39 billion by 2030, at a CAGR of 5.3% during the forecast period, 2023–2030.\u003c\/p\u003e\n\n\u003cp\u003eThe safety testing of new chemicals is now subjected to stricter global regulations. There is a greater focus on animal welfare and the adoption of alternative testing methods. This has led to the development of new and innovative toxicity testing methods that are faster, more accurate, and more cost-effective than before.\u003c\/p\u003e\n\n\u003cp\u003eHowever, developing and validating new toxicity testing methods can be costly and time-consuming, which can limit their adoption and use by companies and organizations. This factor is expected to restrain the growth of the market.\u003c\/p\u003e\n\n\u003cp\u003eOn the contrary, there is a growing demand for alternative toxicity testing methods that can reduce animal testing and provide faster and more accurate results. This presents an opportunity to develop new and innovative testing methods, such as in vitro assays, organ-on-chip technology, and computational modeling. These factors are expected to create ample growth opportunities for the market in the coming years.\u003c\/p\u003e\n\n\u003cp\u003eSegment Overview\u003cbr\u003e\nThe global early toxicity testing industry is segmented on the basis of technique, toxicity endpoint, end users, and region.\u003cbr\u003e\nBy technique, the market is classified into in vivo, in vitro, and in silico.\u003cbr\u003e\nBy toxicity endpoint, the market is divided into genotoxicity, dermal toxicity, skin toxicity, ocular toxicity, phototoxicity, and others.\u003cbr\u003e\nBy end user, the market is divided into pharmaceutical industry, cosmetic industry, chemical industry, food industry, and others.\u003cbr\u003e\nBy region, the market is classified into North America, Europe, Asia-Pacific, and RoW.\u003c\/p\u003e\n\n\u003cp\u003eRegional Analysis\u003cbr\u003e\nAsia-Pacific is projected to dominate the early toxicity testing industry\u003cbr\u003e\nThe Asia-Pacific region has been witnessing a significant growth in the early toxicity testing industry, due to the increasing demand for new drugs, the rising investments in research and development activities, and the growing awareness of animal welfare.\u003c\/p\u003e\n\n\u003cp\u003eMoreover, the Asia-Pacific region has been attracting significant investments from leading pharmaceutical and biotechnology companies, which are expanding their research and development activities in the region. The increasing number of contract research organizations (CROs) in the region is another factor contributing to the growth of the early toxicity testing industry.\u003c\/p\u003e\n\n\u003cp\u003eKey Market Players\u003cbr\u003e\nLeading players in the global early toxicity testing market include companies such as:\u003cbr\u003e\n• Eurofins Scientific\u003cbr\u003e\n• Wuxi Apptec\u003cbr\u003e\n• Danaher Corporation\u003cbr\u003e\n• Thermo Fisher Scientific, Inc.\u003cbr\u003e\n• Perkinelmer, Inc.\u003cbr\u003e\n• Charles River Laboratories\u003cbr\u003e\n• Bio-Rad Laboratories, Inc.\u003cbr\u003e\n• Labcorp Drug Development\u003cbr\u003e\n• Agilent Technologies, Inc.\u003cbr\u003e\n• Evotec AG\u003c\/p\u003e\n\n\u003cp\u003eRecent Developments\u003cbr\u003e\nApril 2023\u003cbr\u003e\nAgilent Technologies Inc. acquired Avida Biomed, a contract research organization specializing in vitro and in vivo toxicity testing, including ADME\/DMPK studies. This acquisition will expand Agilent's capability in preclinical drug development, including early toxicity testing, and complement its existing portfolio of pharmaceutical research and development solutions.\u003c\/p\u003e\n\n\u003cp\u003eFebruary 2023\u003cbr\u003e\nEvotec received a USD 159 million loan from the European Investment Bank (EIB) to support the development of innovative drug candidates. This funding will support the Company’s R\u0026amp;D activities, equity investments, and the building of the new J.POD biologics manufacturing facility on Evotec’s Campus Curie in Toulouse, France.\u003c\/p\u003e\n\n\u003cp\u003eOctober 2022\u003cbr\u003e\nBio-Rad introduced anti-evolocumab antibodies for preclinical and clinical drug development. These new antibodies facilitate the study of Evolocumab, a monoclonal antibody used to lower cholesterol levels. They will also aid in developing novel therapies for cardiovascular diseases. The antibodies are designed to be highly specific and sensitive, making them valuable tools for researchers in drug discovery and development.\u003c\/p\u003e\n\n\u003cp\u003eJuly 2022\u003cbr\u003e\nInotiv, Inc. acquired genetic toxicology assets from Merck's Bioreliance portfolio to expand its genetic toxicology testing capabilities. The acquisition includes two laboratories, first in Edinburgh, Scotland and another in Carlsbad, California. These laboratories specialize in genetic toxicology testing. This acquisition will enable Inotiv to provide additional genetic toxicology testing services to its clients. This will allow them to identify potential safety issues in their compounds and accelerate the development of safe and effective drugs.\u003c\/p\u003e\n\n\u003cp\u003eJuly 2022\u003cbr\u003e\nWuXi AppTec announced the setup of a global innovation center in Singapore, focusing on developing cutting-edge technologies and solutions, including AI and big data. Furthermroe it focuses on accelerating drug discovery and development. The center will also house the company's existing drug screening \u0026amp; profiling platform and preclinical development services.\u003c\/p\u003e\n\n\u003cp\u003eKEY BENEFITS\u003cbr\u003e\n• The early toxicity testing market report provides a quantitative analysis of the current market and estimations from 2023 to 2030.  This analysis assists in identifying prevailing market opportunities.\u003cbr\u003e\n• The study comprises a deep-dive analysis of the early toxicity testing market trends, including current and future trends to depict prevalent investment pockets in the market.\u003cbr\u003e\n• The information related to key drivers, restraints, and opportunities and their impact on the early toxicity testing market is provided in the report.\u003cbr\u003e\n• The competitive analysis of the market players along with their market share in the early toxicity testing market is provided in the report.\u003cbr\u003e\n• The SWOT analysis and Porter’s Five Forces model have been elaborated in the study.\u003cbr\u003e\n• The value chain analysis in the market study provides a clear picture of the role of stakeholders.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"May, 2023 \/ 306 Pages \/ MCW16229714","offer_id":47646993285426,"sku":null,"price":4770.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/early-toxicity-testing-market-by-technique-in-vivo-in-vitro-and-in-silico-by-toxicity-endpoint-genotoxicity-dermal-toxicity-skin-toxicity-ocular-toxicity-phototoxicity-and-others-by-end-user-pharmaceutical-industry-cosmetic-industry-chemic","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}